Metastasis-directed therapy (MDT) significantly improved outcomes in patients with oligometastatic prostate cancer, according ...

The FDA accepted a supplemental biologics license application and granted priority review for Datroway for adults ...

“Exelixis Announces U.S. FDA Accepted the New Drug Application for Zanzalintinib in Combination with an Immune Checkpoint ...

The sBLA is supported by results from the pivotal phase 3 TROPION-Breast02 clinical trial (NCT05374512), which evaluated the efficacy and safety of Dato-DXd compared with the investigator’s choice of ...

Zanzalintinib is an investigational oral agent that inhibits tyrosine kinase receptors associated with cancer growth, including TYRO3, VEGF, MET, AXL, and MER.

A retrospective analysis finds that patients with lung-only metastatic pancreatic cancer have better overall survival, are ...

Significantly longer progression-free survival seen with addition of palbociclib to maintenance anti-HER2 and endocrine therapies.

An interdisciplinary multi-center research team led by the LKS Faculty of Medicine (HKUMed) and Faculty of Dentistry at the ...

Low-dose aspirin may limit cancer metastasis by inhibiting platelet activation and enhancing T-cell immunity, supporting biomarker guided use while balancing bleeding risk overall.

Investigators evaluated dual immune checkpoint inhibitors for safety and efficacy in patients with brain metastases from rare cancers.

HER2 and ABCC1 are identified as significant transcriptomic predictors of overall survival in patients treated with T-DXd. A large-scale analysis reveals novel predictors of survival and resistance ...

Chemotherapy reshapes gut bacteria in ways that send powerful signals throughout the body. These signals reprogram immune ...